CN105288512A - Traditional Chinese medicine composition for treating obesity - Google Patents
Traditional Chinese medicine composition for treating obesity Download PDFInfo
- Publication number
- CN105288512A CN105288512A CN201510893761.9A CN201510893761A CN105288512A CN 105288512 A CN105288512 A CN 105288512A CN 201510893761 A CN201510893761 A CN 201510893761A CN 105288512 A CN105288512 A CN 105288512A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating obesity, which comprises the following substances in parts by weight: 20 parts of astragalus root, 10 parts of angelica root, 10 parts of chuanxiong rhizome, 10 parts of tuckahoe, 30 parts of fried bighead atractylodes rhizome, 15 parts of Chinese atractylodes, 20 parts of rhodiola root, 20 parts of sargentgloryvine stem, 10 parts of red sage root, 10 parts of kuh-seng, 20 parts of kudzu root, 10 parts of folium artemisiae argyi, 10 parts of immature bitter orange, 10 parts of balloon flower, 10 parts of costus root, 10 parts of bupleurum, 10 parts of curcuma root, 10 parts of rhubarb, 20 parts of pig nail, 10 parts of keel, 10 parts of oyster, 50 parts of fried coix seed, 10 parts of rhizoma alismatis, 20 parts of loofah sponge, 10 parts of fructus psoraleae, 10 parts of red ginseng, 10 parts of American ginseng, 10 parts of rhizoma cimicifugae, 10 parts of schisandra, 10 parts of acanthopanax bark and 10 parts of radix glycyrrhizae preparata. The traditional Chinese medicine composition provided by the invention has the effects of strengthening the spleen and replenishing qi, promoting blood circulation and regulating the flow of qi, relaxing bowels and resolving stagnation as well as reducing turbidity and dissipating excessive fluid, thereby achieving the purpose of treatment; and the traditional Chinese medicine composition is free of side effects.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of Chinese medicine composition for the treatment of of obesity.
Background technology
The traditional Chinese medical science is just on the books as far back as Huangdi's Internal Classics, and people has fertilizer, has cream, there is meat, point out fat feature: figure is fat, greasiness, blood glues silk fabric, run slowly this be the disease of Sorghum vulgare Pers. also, people's many surfeit delicious food savoury of obesity, hinders taste, make dysfunction of the spleen in transportation, essence of water and grain can not change promoting generation of vital essence and blood, form cream fat expectorant turbid in store, store and form obesity in skin; Taste excess-heat rapid digestion of food is apt to flesh, polyphagia polydipsia and cause QI and blood and have a surplus, change cream fat and in store and also can cause fat; Liver controlling conveyance and dispersion, if long-term feelings will not the depressed expectorant of Shu Ze coagulate, or catharsis imbalance and cause dysfunction of the spleen in transportation, raw in phlegm-damp; The main water of kidney, deficiency of kidney-QI then can not promote the circulation of qi and water, and causes in turbid damp and stop, and overflow in skin, and it is fat to cause fat; Worn with age, vital organs of the human body hypofunction, essence of water and grain also can not can cause and stop in turbid damp and cause fat fat by normal defeated cloth.
Modern medicine study shows, obesity has become in society the root causing various disease, and data show according to statistics, and in obese people, the obese patient of 90% suffers from the three-hypers diseases such as hypertension, hyperlipidemia, hyperglycemia; The obese patient of 70% suffers from coronary heart disease, cardiovascular disease, has the patient of 50% to have the diseases such as gout, cholelithiasis, cholecystitis simultaneously; The obese patient of 78% can change into diabetes, insulin deficiency, wherein has again the patient of 90% to there will be the diseases such as acute and chronic pancreatitis; The obese patient of 90% suffers from cerebral arteriosclerosis, cerebral thrombosis, the real tune of brain kinetic energy microcirculation, and wherein majority there will be the diseases such as apoplexy, hemiplegia and numb limbs and tense tendons; Senile obese patient also there will be the diseases such as dementia, insomnia, forgetful and osteoporosis.The annual obese patient of current China just increases with the ratio of 5%, and occurred to infant, children and adolescents etc. become younger development trend, China is every year because treating the various diseases caused by obesity, account for 2 ~ 3% of GDP, as can be seen here, prevention and therapy obesity also becomes the major issue being related to population health and national sustainable development.
Obesity causes the too much accumulation of body fat because the absorption of energy exceedes the consumption of energy, and make body fat overheap, body weight increases.Definite obesity definition refers to body fat abnormal increase, but not the exceeding standard of body weight.According to the cause of disease, obesity can be divided into pure and Secondary cases two class.Simple Obesity refers to only have obesity and without the obesity of any organic disease.Simple Obesity can be divided into again the acquired obesity of the constitutional obesity of onset childhood and adult onset.Simple Obesity may change with the appetite stimulator of inherited genetic factors, central nervous system, endocrine function, metabolic factor and sit quietly, the living habit of polyphagia etc. is relevant.Secondary Obesity is secondary to the cause of disease of the Simple Obesity such as some disease is as early stage in the inflammation of hypothalamus one hypophysis, tumor, wound, hypercortisolism, hypothyroidism, hypogonadism, patients with type Ⅰ DM, insulinoma more and pathogenesis still imperfectly understands, may be relevant with following factors.Inherited genetic factors, epidemiology shows some overweight people family's morbidity tendency.Neuropsychical facto, zoopery and clinical observation show the ingested regulating action of nervous and mental factors to people.Endocrine factors, many hormones such as thyroxine, insulin, glucocorticoid etc. may take part in the pathogenesis of obesity.Life style and dietary habit, do not like that movable people's consumed energy reduces, easily obesity occur.Athlete is after stop motion, often take the photograph people's height calorie diet or heavy, smoker after smoking cessation, Food intake before bed custom, like eating greasy food, every day the few and food-intake of often eating of number of times of having meal large etc. all relevant with the generation of Simple Obesity, but be not unique cause of disease.
The most of slimming medicine of domestic and international slimming medicine present situation such as appetite suppressant, diuretic, cathartic etc. have the side effect of varying degree.Slimming medicine salable mainly contains in the world at present: the sibutramine in Germany (Ke Nuo) KNOLL pharmaceutical factory; The orlistat of Roche Holding Ag of Switzerland.The proposition of this concept of losing weight is only thing about ten years in China, and diet products are through having walked the renewal course of develop rapidly.The mid-90 in 20th century, weight-reducing product market experienced by twice product renewal so far.The first generation is rushed down clearly type diet products and is mostly improved by traditional diet tea, utilizes Folium Camelliae sinensis esterified greasy effect of dispelling to lose weight.In order to embody the effect of quick weight-lossing, some producers add in diet tea dosage not wait cathartic as Chinese herbal medicine such as Radix Et Rhizoma Rhei, Natrii Sulfas and sennaes, by the moisture in the mode human body of diarrhoea and protein, what cause is the illusion lost weight, and but fails to touch the basic of obesity.These diet teas of long-term taking, also can cause damage to function of human body, occur the symptoms such as habitual diarrhea, gastrointestinal dysfunction and human body dehydration.The hungry substituted type diet products of the second filial generation reach fat-reducing object by " going on a diet ", namely replace normal diet with low-calorie diet, to reduce the absorption of human body to fat, saccharide, rely on the consumption of human body own fat to carry out makeup energy.In order to cause the sensation of " having had enough ", in some substituted type diet food, also add the medicine (inactive in the U.S. at present) such as appetite suppressant fenfluramine, An Feila ketone.Life-time service can make health be in starvation, not only reduces the mobility of body each side, once cut out, body weight just can quick rebound.Third generation health type diet products with World Health Organization (WHO) propose do not suffer from diarrhoea, do not go on a diet and not weak for fat-reducing principle, effect increases than the first generation, second filial generation diet products.
Commercially the medicine of prevention and therapy obesity, health product are multifarious, of a great variety, principle of its fat-reducing is absorbed as means with appetite-suppressing and oil-control, wherein science and by the generally accepted mode of patient be exactly adjustment the mankind dietary structure, improve food quality, reduce human body to the intake of oils and fats, meat, eggs and carbohydrate food, shortcoming is the reduction of the mankind's enjoying to the full ambrosia.And there is the side reaction affecting the functions such as liver, kidney, heart sometimes in these medicines by oral fat-reducing, health product.Medical research simultaneously shows, oils and fats in body fat, mainly contain two class chemical substance compositions, one class is that satisfied fatty acid fat accounts for 79% of fatty oils and fats, belong to not easily oxidized, decompose, the material of metabolism, be easy to be gathered in subcutaneous fat, sometimes during this kind of material intravasation circulation, also easily form thrombosis condensation product, occlude blood mobility, increase the stickiness of blood, reduce blood flow, thus brain keeping deficiency can be produced, cause vasospasm and contraction, cause coronary heart disease, cardiovascular disease, cerebral arteriosclerosis, apoplexy, hemiplegia and dementia wait disease.This is also main harmful material that obese patient falls ill.Another kind of is that unsaturated fatty acid accounts for 20% of total fatty oils and fats, it is the material that a class is absorbed by the body, transforms, also be the energy component of each organ metabolic demand of human body, this constituents also has effect of thrombosis, arrhythmia, anti-cerebral arteriosclerosis in antiinflammatory, anti-blood in human body simultaneously, is the material useful to human body.Modern medicine study confirms, unsaturated fatty acid prevents the effect of the diseases such as coronary heart disease, cardiovascular disease, diabetes, cancer, hepatitis, cerebral arteriosclerosis, apoplexy, hemiplegia, dull-witted depression, psychotic disorder, rheumatoid and rheumatic arthritis, neurodermatitis, emphysema, asthma, nephritis in addition, and the important composition material of this kind of material or human brain liposome.How neither to affect human body healthy, effectively controlling again fat, to reach attractive in appearance and healthy object be need the technical barrier of solution badly.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition for the treatment of of obesity.
In order to realize object of the present invention, the invention provides a kind of Chinese medicine composition for the treatment of of obesity, it comprises the material of following weight portion: the Radix Astragali 20 parts, Radix Angelicae Sinensis 10 parts, Rhizoma Chuanxiong 10 parts, 10 parts, Poria, Rhizoma Atractylodis Macrocephalae (parched) 30 parts, Rhizoma Atractylodis 15 parts, Radix Rhodiolae 20 parts, Caulis Sargentodoxae 20 parts, Radix Salviae Miltiorrhizae 10 parts, Radix Sophorae Flavescentis 10 parts, Radix Puerariae 20 parts, Folium Artemisiae Argyi 10 parts, Fructus Aurantii Immaturus 10 parts, Radix Platycodonis 10 parts, the Radix Aucklandiae 10 parts, Radix Bupleuri 10 parts, Radix Curcumae 10 parts, Radix Et Rhizoma Rhei 10 parts, Unguis Sus domestica 20 parts, Os Draconis 10 parts, Concha Ostreae 10 parts, Semen Coicis (parched) 50 parts, Rhizoma Alismatis 10 parts, Retinervus Luffae Fructus 20 parts, Fructus Psoraleae 10 parts, Radix Ginseng Rubra 10 parts, Radix Panacis Quinquefolii 10 parts, Rhizoma Cimicifugae 10 parts, Fructus Schisandrae Chinensis 10 parts, Cortex Acanthopancis 10 parts and Radix Glycyrrhizae Preparata 10 parts.
Preferably, the Chinese medicine composition for the treatment of of obesity of the present invention also comprises the material of following weight portion: the 4-(5-cyclobutyl-4-morpholine-4-base-pyrido [3 of 0.05 part, 4-d] pyrimidine-2-base)-9H-pyrido [2,3-b] indole.Such as, 4-(5-cyclobutyl-4-morpholine-4-base-pyrido [3,4-d] pyrimidine-2-base)-9H-pyrido [2,3-b] indole is disclosed in CN105102456A.
More preferably, described Chinese medicine composition can be tablet, dispersible tablet, capsule, pill or decoction.
The present invention also provides the purposes of 4-(5-cyclobutyl-4-morpholine-4-base-pyrido [3,4-d] pyrimidine-2-base)-9H-pyrido [2,3-b] indole in the medicine of preparation treatment of obesity.
Preferably, described medicine can be tablet, dispersible tablet, capsule, pill or decoction.
Chinese medicine composition of the present invention can the effect such as invigorating the spleen and benefiting QI, blood circulation promoting regulates qi, purging FU-organs intestinal stasis relieving, the turbid descending dissipating fluid-retention, thus reaches the object for the treatment of, and has no side effect.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment
Take the Radix Astragali 20 grams, Radix Angelicae Sinensis 10 grams, Rhizoma Chuanxiong 10 grams, 10 grams, Poria, Rhizoma Atractylodis Macrocephalae (parched) 30 grams, Rhizoma Atractylodis 15 grams, Radix Rhodiolae 20 grams, Caulis Sargentodoxae 20 grams, Radix Salviae Miltiorrhizae 10 grams, Radix Sophorae Flavescentis 10 grams, Radix Puerariae 20 grams, Folium Artemisiae Argyi 10 grams, Fructus Aurantii Immaturus 10 grams, Radix Platycodonis 10 grams, the Radix Aucklandiae 10 grams, Radix Bupleuri 10 grams, Radix Curcumae 10 grams, Radix Et Rhizoma Rhei 10 grams, Unguis Sus domestica 20 grams, Os Draconis 10 grams, Concha Ostreae 10 grams, Semen Coicis (parched) 50 grams, Rhizoma Alismatis 10 grams, Retinervus Luffae Fructus 20 grams, Fructus Psoraleae 10 grams, Radix Ginseng Rubra 10 grams, Radix Panacis Quinquefolii 10 grams, Rhizoma Cimicifugae 10 grams, Fructus Schisandrae Chinensis 10 grams, Cortex Acanthopancis 10 grams and Radix Glycyrrhizae Preparata 10 grams, pulverize, cross 100 mesh sieves, mix homogeneously obtains powder.
Experimental example
Modeling and grouping
Kunming mouse, 60, body weight 20 ± 2g, male and female half and half, every two cages are raised.Be divided into 6 groups at random, often organize 10, wherein one group is blank, feeding normal diet, all the other 5 groups of feeding high lipid foods.By every every day 10g food-intake, take feedstuff feeding record feeding amount every day.At 9 in morning next day removes ate surplus feedstuff the day before yesterday, record residual feed weight.Continuous nursing 3 weeks, weekly routine weighing twice, until matched group and common group of body weight there were significant differences, modeling success.
Pharmacodynamic experiment
Weigh Mouse Weight, determine that oneself forms obese model, 5 treated animals of feeding high lipid food are divided into model group, positive controls, administration group 1, administration group 2, administration group 3.Every treated animal is still equally fed by modeling, every day quantitative feeding high lipid food.Gavage 0.4ml 5/1000ths sodium carboxymethyl cellulose solution before feeding every day of model group animal; Positive control treated animal gavage Sibutramine Hydrochloride 1.5mg/kg; Administration group 1, the powder 2g of embodiment adds 2000mL normal saline and becomes suspension, gives gavage 1mL/1000g body weight; 4-(5-cyclobutyl-4-morpholine-4-base-pyrido [3,4-d] pyrimidine-2-base)-9H-pyrido [2, the 3-b] indole of administration group 2,0.02g adds 2000mL normal saline and becomes suspension, gives gavage 1mL/1000g body weight; Administration group 3,4-(5-cyclobutyl-4-morpholine-4-base-the pyrido [3 of powder 1g and 0.01g of embodiment, 4-d] pyrimidine-2-base)-9H-pyrido [2,3-b] indole adds 2000mL normal saline and becomes suspension, gives gavage 1mL/1000g body weight.Once a day.After 17 days, respectively organize mouse weights, push away cervical dislocation place post mortem, measure mice nose long as body to the length of anus, calculate Lee ' s index according to the following formula:
The results are shown in following table.(n＝10
)
| Group | Lee ' s index |
| Blank group | 305.46±14.1 |
| Model group | 376.85±14.8 |
| Positive drug group | 331.37±12.9* |
| Administration group 1 | 355.17±14.3* |
| Administration group 2 | 342.61±13.2* |
| Administration group 3 | 353.82±13.5* |
Note: compare * P < 0.05 with model group.
Claims (5)
1. the Chinese medicine composition of a treatment of obesity, it is characterized in that, it comprises the material of following weight portion: the Radix Astragali 20 parts, Radix Angelicae Sinensis 10 parts, Rhizoma Chuanxiong 10 parts, 10 parts, Poria, Rhizoma Atractylodis Macrocephalae (parched) 30 parts, Rhizoma Atractylodis 15 parts, Radix Rhodiolae 20 parts, Caulis Sargentodoxae 20 parts, Radix Salviae Miltiorrhizae 10 parts, Radix Sophorae Flavescentis 10 parts, Radix Puerariae 20 parts, Folium Artemisiae Argyi 10 parts, Fructus Aurantii Immaturus 10 parts, Radix Platycodonis 10 parts, the Radix Aucklandiae 10 parts, Radix Bupleuri 10 parts, Radix Curcumae 10 parts, Radix Et Rhizoma Rhei 10 parts, Unguis Sus domestica 20 parts, Os Draconis 10 parts, Concha Ostreae 10 parts, Semen Coicis (parched) 50 parts, Rhizoma Alismatis 10 parts, Retinervus Luffae Fructus 20 parts, Fructus Psoraleae 10 parts, Radix Ginseng Rubra 10 parts, Radix Panacis Quinquefolii 10 parts, Rhizoma Cimicifugae 10 parts, Fructus Schisandrae Chinensis 10 parts, Cortex Acanthopancis 10 parts and Radix Glycyrrhizae Preparata 10 parts.
2. the Chinese medicine composition for the treatment of of obesity according to claim 1, it is characterized in that, it also comprises the material of following weight portion: 4-(5-cyclobutyl-4-morpholine-4-base-pyrido [3,4-d] pyrimidine-2-base)-9H-pyrido [2, the 3-b] indole of 0.05 part.
3. the Chinese medicine composition for the treatment of of obesity according to claim 1 and 2, is characterized in that, described Chinese medicine composition can be tablet, dispersible tablet, capsule, pill or decoction.
The purposes of 4.4-(5-cyclobutyl-4-morpholine-4-base-pyrido [3,4-d] pyrimidine-2-base)-9H-pyrido [2,3-b] indole in the medicine of preparation treatment of obesity.
5. purposes according to claim 4, is characterized in that, described medicine can be tablet, dispersible tablet, capsule, pill or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510893761.9A CN105288512A (en) | 2015-12-08 | 2015-12-08 | Traditional Chinese medicine composition for treating obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510893761.9A CN105288512A (en) | 2015-12-08 | 2015-12-08 | Traditional Chinese medicine composition for treating obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105288512A true CN105288512A (en) | 2016-02-03 |
Family
ID=55186789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510893761.9A Pending CN105288512A (en) | 2015-12-08 | 2015-12-08 | Traditional Chinese medicine composition for treating obesity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105288512A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105102456A (en) * | 2012-09-28 | 2015-11-25 | 易格尼塔公司 | Azaquinazoline inhibitors of atypical protein kinase C |
-
2015
- 2015-12-08 CN CN201510893761.9A patent/CN105288512A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105102456A (en) * | 2012-09-28 | 2015-11-25 | 易格尼塔公司 | Azaquinazoline inhibitors of atypical protein kinase C |
Non-Patent Citations (1)
| Title |
|---|
| 王红英等: "清瘀化痰饮配合西药治疗代谢综合征及对体重指数的影响", 《陕西中医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102886038B (en) | Traditional Chinese medicine preparation for losing weight and preparation method of traditional Chinese medicine preparation | |
| CN101698028B (en) | Fat-reducing and weight-losing composite and preparation method thereof | |
| CN1093405C (en) | Defatting tea | |
| CN103877263B (en) | A kind of antifatigue health preparation of the compound Chinese medicine such as red ginseng, maca, green-tea extract (theanine) | |
| CN103721045B (en) | For improving the Chinese traditional immunopoteniators of broiler immunologic function in growth course | |
| CN104338043B (en) | A kind of medicine for improving immunity and preparation method thereof | |
| CN101053621B (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
| CN100435839C (en) | Fat-regulating and liver-tonifying type medicine for treating adiposis hepatica | |
| CN101837087B (en) | Chinese medicinal composition for improving immunity, resisting fatigue and improving sexual function | |
| CN103301413A (en) | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia | |
| CN103041209A (en) | Chinese herbal preparation for curing deficiency of kidney-yin and preparation method thereof | |
| CN103816519A (en) | Spleen-strengthening dampness-removing traditional Chinese medicine composition and preparation method thereof | |
| CN103285145A (en) | Pure traditional Chinese medicine preparation for prompting rapid growth of pigs as well as preparation method and application method thereof | |
| CN103877438B (en) | Traditional Chinese medicine preparation for treating gout and production method thereof | |
| CN106994141B (en) | Traditional Chinese medicine composition for treating constipation and preparation method thereof | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN106913711A (en) | Treat pharmaceutical composition of knee osteoarthritis and preparation method thereof | |
| CN102688445A (en) | Traditional Chinese medicine for treating diabetes and preparation method thereof | |
| CN105456566A (en) | Medicine for treating gynecological disease and preparation method thereof | |
| CN105062810A (en) | Saussurea involucrate prepared wine and preparation method thereof | |
| CN104800771A (en) | Traditional Chinese medicine preparation for treating children sleep terror disorder and preparation method thereof | |
| CN104524292A (en) | Application of traditional Chinese medicine preparation in preparation of medicament for treating obesity | |
| CN103054073A (en) | Beautifying fish scale jelly and preparation method thereof | |
| CN105288512A (en) | Traditional Chinese medicine composition for treating obesity | |
| CN102698099A (en) | Pill for treating diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160203 |